Yesterday, Congressman John Sarbanes, D-Maryland, introduced the Biosimilars Competition Act of 2018 in the United States House of Representatives. The bill would require biologic and biosimilar drug manufacturers to report any agreements they enter into that may keep lower-cost drugs from reaching consumers.
Yesterday, Congressman John Sarbanes, D-Maryland, introduced the Biosimilars Competition Act of 2018 in the United States House of Representatives. The bill would require biologic and biosimilar drug manufacturers to report any agreements they enter into that may keep lower-cost drugs from reaching consumers.
“This bill will help lower prescription drug costs by bringing more affordable biosimilar drugs to the market,” said Congressman Sarbanes in an email to The Center for Biosimilars®. “Some biologic drug manufacturers make deals with biosimilar manufacturers to keep biosimilars off the market, retain their market share, and keep prices high.”
A number of these agreements have made the news and come under more scrutiny recently. Specifically, pharmaceutical manufacturer AbbVie recently struck its third agreement with a biosimilar developer over Humira. AbbVie currently has similar deals in place with Mylan, Samsung Bioepis, and Amgen, each one staving off biosimilar competition for Humira in the United States until 2023.
AbbVie faced criticism over such settlements as earlier this month, when Senators Chuck Grassley, R-Iowa, and Amy Klobuchar, D-Minnesota, urged the Federal Trade Commission (FTC) to investigate whether these settlements are “pay-for-delay” tactics designed to keep patients from accessing cheaper medications.
Delays of biosimilar market entry have also garnered more attention lately, as the FDA Commissioner Scott Gottlieb, MD, announced with the release of the Biosimilar Action Plan initiatives that the FDA will be implementing to further spur competition, as well as a partnership between the FDA and the FTC to address anticompetitive behaviors.
“[Biosimilar] competition is, for the most part, anemic…we’re not going to play regulatory whack-a-mole with companies trying to unfairly delay or derail the entry of biosimilar competitors,” said Gottlieb.
Notably, the bill introduced by Sarbanes will not allow the FTC to retrospectively investigate such agreements. Instead, “The bill we introduced [yesterday] will require biologic manufacturers and biosimilars manufacturers to submit all deals to the FTC and the Department of Justice for review so that they can monitor these agreements and take action against bad actors,” he said.
Congressman Sarbanes noted that he’s hopeful that “this bipartisan bill—one that will help lower prescription drug prices and save millions of dollars for hardworking Americans—will be considered by the full [House of Representatives] or included as part of another legislative package that comes to the floor.”
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).